CO2020015758A2 - Compuestos de purinona y su uso en el tratamiento del cáncer - Google Patents

Compuestos de purinona y su uso en el tratamiento del cáncer

Info

Publication number
CO2020015758A2
CO2020015758A2 CONC2020/0015758A CO2020015758A CO2020015758A2 CO 2020015758 A2 CO2020015758 A2 CO 2020015758A2 CO 2020015758 A CO2020015758 A CO 2020015758A CO 2020015758 A2 CO2020015758 A2 CO 2020015758A2
Authority
CO
Colombia
Prior art keywords
compounds
salts
cancer
treatment
methods
Prior art date
Application number
CONC2020/0015758A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Frederick Woolf Goldberg
Martin Richard Howard
Attilla Kuan Tsuei Ting
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of CO2020015758A2 publication Critical patent/CO2020015758A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (I) y sales farmacéuticamente aceptables de los mismos, donde R1, A1, A2 y A3 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir una enfermedad mediada por PC-ADN, incluyendo el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales; kits que comprenden tales compuestos y sales; métodos de fabricación de dichos compuestos y sales; intermedios útiles en la fabricación de dichos compuestos y sales; y a los métodos para tratar una enfermedad mediada por PC-ADN, incluyendo el cáncer, usando dichos compuestos y sales.
CONC2020/0015758A 2018-06-15 2020-12-15 Compuestos de purinona y su uso en el tratamiento del cáncer CO2020015758A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15
PCT/EP2019/065686 WO2019238929A1 (en) 2018-06-15 2019-06-14 Purinone compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CO2020015758A2 true CO2020015758A2 (es) 2021-04-30

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0015758A CO2020015758A2 (es) 2018-06-15 2020-12-15 Compuestos de purinona y su uso en el tratamiento del cáncer

Country Status (29)

Country Link
US (2) US11884671B2 (es)
EP (1) EP3807278B1 (es)
JP (1) JP7472044B2 (es)
KR (1) KR20210020944A (es)
CN (1) CN112236431B (es)
AR (1) AR114971A1 (es)
AU (1) AU2019287295B2 (es)
BR (1) BR112020025127A2 (es)
CA (1) CA3102195A1 (es)
CL (1) CL2020003131A1 (es)
CO (1) CO2020015758A2 (es)
CR (1) CR20200620A (es)
DO (1) DOP2020000241A (es)
EA (1) EA202190006A1 (es)
EC (1) ECSP20080276A (es)
ES (1) ES2931448T3 (es)
IL (1) IL279370A (es)
JO (1) JOP20200315A1 (es)
MA (1) MA52886A (es)
MX (1) MX2020013570A (es)
NI (1) NI202000099A (es)
PE (1) PE20210003A1 (es)
PH (1) PH12020552148A1 (es)
SG (1) SG11202012035WA (es)
TW (1) TWI820146B (es)
UA (1) UA126837C2 (es)
UY (1) UY38263A (es)
WO (1) WO2019238929A1 (es)
ZA (1) ZA202100195B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202110849A (zh) * 2019-05-27 2021-03-16 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
KR20220106799A (ko) * 2019-11-25 2022-07-29 메드샤인 디스커버리 아이엔씨. Dna-pk 억제제로서의 피리미도이미다졸계 화합물
WO2021136462A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
KR20220107026A (ko) 2019-12-31 2022-08-01 청두 바이위 파머수티컬 씨오., 엘티디 퓨린 유도체 및 의학에서의 그의 용도
CN113121573A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
WO2021204111A1 (zh) * 2020-04-10 2021-10-14 南京明德新药研发有限公司 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2022017368A1 (zh) * 2020-07-20 2022-01-27 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
CN116685323A (zh) * 2020-12-21 2023-09-01 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
TW202229281A (zh) * 2020-12-24 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CN117377676A (zh) * 2021-06-29 2024-01-09 成都百裕制药股份有限公司 嘌呤衍生物的晶型及其药物组合物
WO2023036156A1 (zh) * 2021-09-07 2023-03-16 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2696200A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
EP2417138B1 (en) * 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
JP5759471B2 (ja) 2009-10-29 2015-08-05 ヴェクチュラ リミテッド Ｊａｋ３キナーゼ阻害剤としての窒素含有ヘテロアリール誘導体
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
SG10201601909TA (en) * 2011-03-11 2016-04-28 Gilead Calistoga Llc Combination Therapies For Hematologic Malignancies
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
SI3558997T1 (sl) * 2016-12-20 2021-07-30 Astrazeneca Ab Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka

Also Published As

Publication number Publication date
AU2019287295B2 (en) 2022-05-26
CR20200620A (es) 2021-03-09
UY38263A (es) 2019-12-31
BR112020025127A2 (pt) 2021-03-23
WO2019238929A1 (en) 2019-12-19
SG11202012035WA (en) 2021-01-28
AU2019287295A1 (en) 2021-02-04
MA52886A (fr) 2021-04-21
EA202190006A1 (ru) 2021-03-29
IL279370A (en) 2021-01-31
ES2931448T3 (es) 2022-12-29
KR20210020944A (ko) 2021-02-24
US20210171525A1 (en) 2021-06-10
JP7472044B2 (ja) 2024-04-22
UA126837C2 (uk) 2023-02-08
JP2021527095A (ja) 2021-10-11
DOP2020000241A (es) 2021-04-30
PH12020552148A1 (en) 2021-07-05
CA3102195A1 (en) 2019-12-19
TW202035410A (zh) 2020-10-01
JOP20200315A1 (ar) 2020-12-07
ECSP20080276A (es) 2021-01-29
EP3807278B1 (en) 2022-08-31
NI202000099A (es) 2021-09-24
TWI820146B (zh) 2023-11-01
EP3807278A1 (en) 2021-04-21
CL2020003131A1 (es) 2021-04-30
MX2020013570A (es) 2021-05-27
PE20210003A1 (es) 2021-01-05
AR114971A1 (es) 2020-11-11
US11884671B2 (en) 2024-01-30
CN112236431B (zh) 2024-02-13
CN112236431A (zh) 2021-01-15
ZA202100195B (en) 2022-08-31
US20240150355A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR20190361A (es) Dendrímeros terapéuticos
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)